



The Economics of Apothecaries: Guilds, Pricing, and Consumer Access

Anurag verma¹, Pragati jain^{1*}, Ashish Kumar Gupta²

¹Department of Pharmaceutics, Teerthankar Mahaveer College of Pharmacy, Teerthankar Mahaveer University, Moradabad, 244001, Uttar Pradesh, India.

² School of Pharmaceutical & Biological Science, Harcourt Butler Technical University, Kanpur, Uttar Pradesh- 208002, India.

Co-responding author

Pragati Jain

Department of Pharmaceutics, Teerthankar Mahaveer College of Pharmacy, Teerthankar Mahaveer University, Moradabad, 244001, Uttar Pradesh, India. ORCID ID: 0009-0000-3857-0613 Email ID: jainpragati.pharmacy@gmail.com

Abstract

The economics of the European apothecary can be measured by simple data regarding the institution 's membership, pricing, and targeted audience. The apothecary guilds grew exponentially from the 14th century to the 18th century records show that over 120 apothecary guilds existed in the 1700's in large European cities. Numbers of members differed from place to place. London 's two guilds, for example, Boasts and the Apothecaries Hall, had 312 licensed practitioners in 1650, and Paris in 1680 boasted 278 members. Pricing was tightly controlled local ordinances made a certain formula (for example, a standard herbal poultice costing 2-3 shillings) the standard. Other elixirs would be marked up 300-400% costing 8-12 shillings when raw ingredients cost 2-3. Consumer access also varied drastically by class, gender, and city size. Urban upper classes had near complete access, whereas survey data on the merchant class indicates one 85% of urban, middle-class households made purchases from the apothecary, 25% of rural ones. There were also huge differences in the presence of this market between locations: in Italy, 92% of towns greater than 5,000 had an apothecary, in Germany less than 40% of country towns did. Guilds made monopolies, founding's fines of 5-10 florins. This paper fits the apothecary into the framework of European economic history by addressing all of these points with quantitative data. In doing so, the research demonstrates the dual uses of pharmaceuticals: they were necessities for health and economic commodities that had their prices and target audiences controlled. The quantitative data, although sparse, speaks to the future of drugs: the same pricing and access issues that plagued 17th century Europe haunt us still.

Key Words: Apothecaries; Guilds; Pricing; Consumer Access; Economic History

Introduction

Historical background of apothecaries in Europe

European apothecaries appear in the 12th century, having developed from the sale and manufacture of medicaments that broke away from general merchanting. They had devised themselves by then into a middle group of practitioners, combining commercial and medical activity, and guilds began to govern their practice from the 14th century onwards,

mushrooming across Europe into the 17th century, regulating practice and regulating economics[1,2]. In such major urban centers as London, Paris and Florence, the apothecary was, like the pharmacist in the modern age, an important, middleman figure, bridging the gap between doctor and layman by preparing drugs and remedies from minerals, herbs and animals. They regulated practice by training, but also set their prices, the regulation over the economy of urban life that guilds found so important [3,4] . Ordinances, for example, set charges for what we would now call standard cures, and guild monopolies imposed on outsiders' fines and other costs. Availability of apothecaries to consumers also differed. In cities the richer sections of society had ready access to the ringside seats of the apothecary 's shop. Conversely the rurales had their access somewhat restricted. This portrays the complex relationship between medicine and business and social class. Hence the apothecaries, are placed in the context of European economic history[5,6].

The rise of guilds and their economic role

The development of apothecary guilds across Europe between the 14th and 17th centuries established the new medical order. Apothecaries as collegial groups of practitioners who initially organized that began as informal networks fulfilling the demand for books and legal documents soon legislated their trades, and began to monopolize their affairs by restricting entry by gates of an average of 5-7 years [7,8] , controlling competition, through fines of 5-10 florin for unqualified sellers, and setting prices. guilds limited equal access to pharmaceutical markets, conferring monopoly status on their ranks and dictating not only the flow of trade but the price at which it would flow. In 1601 a pricing ordinance set a standard 2-3 shillings for most herbal decoctions, 10 shillings for complex compounds. The distribution of apothecary shopkeepers in cities, the burden of guild taxes on the common people, and the enrichment of municipalities all testify to the influence of apothecary guilds as a political economic force in Europe as well as a professional organization[9,10].

Pricing mechanisms in pre-industrial economies

In preindustrial Europe the prices of pharmaceutical commodities reflected a mixture of market operations, guild regulation and municipal regulation. Apothecaries were part of tightly regimented systems where guilds issued price lists to avoid undercutting and maintain consistency. Until the late 16th century many cities, including both London and Paris, mandated apothecaries to hang displays of prices with 2-3 shillings being typical for most general herbal substances and complex compounds ranging from 8-12 shillings, a 300-400% mark-up on the actual costs of the raw materials needed[11,12]. The availability (or lack) of raw materials also had an effect on prices. Importation of foreign spices or plants from Asia and the New World could have a factor of 5-10 times the price of native herbs with the price of compounded medicines being pushed even higher. Prices varied according to seasonal availability; evidence from 17th century Florence indicates a rise of up to 20-30% during a poor harvest. Cost was not the only relevance for different classes of consumers. The urban elite could absorb higher costs, but the proportion of merchant households regularly purchasing herbal remedies was over 80% in survey work. By contrast rural inhabitants were often unable to purchase herbal substances because of financial constraints and restricted accessibility[13,14].

Consumer access and social stratification

The movement of medicines from apothecaries to the consumers was equal parts social and geographical. People of the urban elite could, almost without exception, always access the amenities of the apothecary with merchant households in 17th century London regularly obtaining supplies throughout the period. Conversely, peasantries of rural areas were not so

fortunate and, where survey data exists from regions of Germany, fewer than 30% of rural households with access to an apothecary, and their absence meant reliance upon folk remedies and lay healers [15,16]. Economic status also determined the amount of products used; higher socioeconomic ranking groups could afford expensive 8–12 shilling compounds but working-class groups could only access herbal preparations at a cheaper 2–3 shilling. This limited access by rural laypeople to professional products had a consequential knockon health security, and the evolution of the apothecary system and the price disparity between class context meant that the higher echelons of society, with the more complex provision of apothecary products, had better health outcomes and higher basic quality of life. Guild monopolies meant all apothecaries resided in urban hubs (more than 75% of all registered practitioners resided in towns), at the expense of rural dwellers. Literacy also accounted for class differentials: while use of written documents was more critical for the middle classes and those interacting with it, the more illiterate peer groups would rely on oral traditions and community experts. Class and geography then determined access to professional medicine for 16th- to 18th-century Europeans [17,18].

Comparative perspectives across European regions

Indeed, the economic position of apothecaries differed between regions of Europe, according to guild arrangements, prices and consumer accessibilities. The Apothecaries' Hall in London acquired monopolistic control by the 17th century, with over 300 licensed herbalists registered by 1650, and tightly regulated the price of herbal products. Prices were fixed at 2–3 shillings, providing consistency for web-using urban consumers. In France, the Societe des Apothicaires assumed combined medical-commercial authority, but as they competed with doctors they frequently contested the boundary between the two. The guild counted 278 members by 1680, and general prices were more flexible, with cured medicines costing 12–15 livres, reflecting urban demand. Guilds in Germany were governed on a municipal basis, but rural areas were underserved, with fewer than 40% of municipalities with populations below 5,000 having apothecaries, reinforcing disparities within Europe. Meanwhile the Italian regions of Florence and Venice linked the apothecaries more closely to trade networks, gained from access to imported botanicals (see figure 4.), and used expensively sourced ingredients to increase medicine prices by five times, so making them available to the highest social strata through networks that linked with human and financial capital [19,20].

Link to broader economic history debates

Apothecaries, and their guild system, directly links to, and supports, the general questions asked by European economic historians; monopoly power and regulation, and individual, consumer inequality. Guilds represent the schism between upholding professional integrity, and limiting market competitiveness. Although they set standards, and protected the quality of their goods, generalists guilds certainly limited competition and raised prices, a theme central to inquiry into the importance of monopolies for preindustrial markets [21,22]. Economic historians have puzzled whether guilds improved efficiency, or prevented experimentation and change, with apothecaries being a glaring example of both side in action. Pricing is another area which supports forms of monopoly and regulation in markets, including a price-fixing scheme in remedies, like herbal decoction costing 2–3s, only infrequently considered in wider questions of government manipulation of prices. Consumer inequality is also a feature, with elites having nearly complete access to medicines in cities, in direct contrast to rural consumers. The inclusion of apothecaries in global trade through imported, expensive exotic

botanicals, like cinchona was also noted and was often valued 5 times more than homely herbs, opening the field to questions of colonial imposition[23–25].




Figure 1. Timeline of apothecary guild development across major European cities, 1100–1800.

Three questions present themselves as framing questions: First, how did guild regulation influence market structure and what were the measurable dimensions of monopoly domination? Second, what was the process of price formation for pharmaceuticals and where was structural stratification located? Third, how could regional and social inequalities be mapped onto consumer access and what can variation tell us about the connection between governance and access to health care across the four nations of England, France, Germany and Italy? [26,27] Combining archival evidence with economic analysis this paper develops a picture of the pre-industrial apothecary not simply as proto-pharmacists but as participants in a regulated commodity market whose constraints presaged many of the paradigms of twentieth-century pharmaceutical economics. This is done by reviewing the literature, describing the archive and methodological approach, presenting results divided by guild regulation, pricing, access and the market, discussing comparisons with other areas, and concluding with a discussion of the heritage of this institutional framework.

Materials and Methods

The paper use forensic economics approach to explore the apothecary, guilds and consumer access of the Europe from 14 thC. to 18thC. The research design is based on archive study, comparative case studies and economic interpretation.

Archival Sources:

- i. **Guild charters:** This study approaches guild charters as the main archival source, with the unifying goal of creating a comparative picture of the regulation of apothecaries in preindustrial Europe. Guild charters have as their subject the regulation of training, membership and prices. Apprenticeship stipulate that practitioners must remain in practice for 5-7 years under the oversight of established practitioners before registering with the guild and practicing alone. Membership regulated the practiced and imposing fees and activities, resulting in a guild monopoly. Price regulations elaborated the prices of emollients established at 2-3 shillings for stock remedies and specific markups for elaborate compound [28,29]. The charters, from England, France, Germany and Italy, demonstrate how guilds worked to balance

monopolist interests on the one hand, and professional credibility with consumer access on the other. They demonstrate the role of guilds as monopolist gate keepers of medical knowledge. This paper aspires to use those charters as a comparative base from which to understand the ways in which guilds operated to shape the pharmaceutical market[30,31].

- ii. **Municipal records:** Municipal records are evidence of the ways in which apothecaries were incorporated into urban economies. Ordinances and decrees by councils regularly set tariffs, guaranteeing that common remedies such as decoctions of herbs cost between 2-3 shillings, while complex compounds might go as high as 10-12 shillings. Notes in these records show fines of between 5-10 florins for unlicensed practitioners, thus upholding guild monopolies and reassuring consumers [32,33] . Taxation records reveal that apothecaries contributed income to the city states through licensing and other fees. All of these sources shed light on the way governing bodies sought to regulate the business of healthcare, augment their revenues, and build consumer confidence[34,35].
- iii. **Trade ledgers:** Trade ledgers allow us to build up the quantitative picture of the pharmaceutical pricing systems of preindustrial Europe. Commercial trade accounts indicate the purchase price of raw materials, import prices and profit margins. For example, by comparing import prices of cinchona bark or cinnamon with the prices of herbs bought locally, we find that imported botanicals can add five to ten times the price of an herbal remedy, and give an understanding of the contribution to overall costs of the various components of compounded medicines [36,37] . Leads estimates can be made from trade accounts by comparing purchase prices and retail tariffs. Florentine apothecaries sub-ranked their purchase prices by 300-400% and these are calibrated by florentine trade accounts to demonstrate the effect of poor harvests on the raw material component by 20-30% of the price of a remedy in the central market in the 17th century. Thus, a second empirical anchor point for the economic study in this chapter can be established[38,39].

Analytical framework

The paper makes use of three analytical approaches taken from economic history. Monopoly theory is employed to analyze guild regulation: the apprentice obligation and the entry fee as protectory devices to uphold monopoly rents; tariff-setting as a capture device to entrench incumbent guild interests. Supply-and-demand analysis is used to study price formation, especially the pricing consequences of import-dependency and seasonal supply-disruptions. Consumer choice analysis, developed with the help of the municipal survey data on access to sales and the guild census information on the access to production, construes the price/space/caste relation in driving consumption variations[40].

This quantitative approach can be supplemented through qualitative inspection of the language in charters and ordinances, which provides interpretive laser-beam energy where hard evidence does not carry. The regional comparison (England, France, Germany, and Italy) is structured through the three axes of regulation, price, and access, which provides for easily translatable cross-national comparisons[41,42].




Figure 2. Regional distribution of licensed apothecary establishments across Europe, c.1650–1700.

Historical- Economic framework

To place the economic history of apothecary commerce in Old World pre-industrial context, three structural features of the pre-industrial world should be highlighted. These are the using of guild monopoly as a regulatory tool, the impact of long-distance trade on prices of commodities, and the link between the social status and developed commerce of towns.

Pre-industrial European economies were not based on free markets in the modern sense of the word, but rather on a complex web of rules, privileges and institutional restrictions on exchange. Guilds represented one of the more significant restrictions, acting as quality-assurance agencies, rent-seeking cartels, or both at the same time, depending on where a given segment of the supply chain was analysed from (Ogilvie, 2011). In the case of the apothecaries, they provided the members with a legal monopoly on the pharmaceutical market, whilst simultaneously imposing steep costs of entry (prolonged apprenticeships, fees) which represented a barrier to entry. The net outcome was a combination of professional regulation and monopoly pricing, effectively transferring money from consumers' pockets to the purveyors' as prices were well above competitive levels.

The integration of European apothecary markets into a web of long-distance trade added a additional layer of complexity. The availability and hence price of imported botanicals, spices, resins, bark and dried plant products from the Levant, the Indian Ocean world and, after the 1490s, the Americas was unstable as wars, pirate attacks, crop failures and proto-mercantilist policies all jeopardized supply. As a result, apothecaries situated in coastal markets connected directly to Mediterranean routes (Venice, Florence, Genoa, Marseille) had a structural cost advantage relative to those operating in inland or Atlantic-facing markets with costly and lengthy supply chains (Gentilcore 1998, Nightingale 1995)[43].

And finally, pre-industrial urban social geography led to demand. The agglomeration of wealth, literacy and institutional infrastructure in urban settings ensured that drug markets were inherently urban: guild-certified practitioners settled where customers were dense, and rational behaviour, with the structural effect of stranding rural populations in chronic neglect, dictated that practice would be procapitalist. Not accidental market failure, but predictable market structure.

Results

Guild Regulation and Monopoly Structure

An archival study confirms that across all four regions studied, apothecary guilds functioned as established monopolies. The primary tools of monopolization were (the rules on) apprenticeship, fees for a license, entry fines paid by unlicensed practitioners, and regulations establishing tariffs.

Apprenticeship contracts in some German towns lasted five years, while in England they lasted seven. Such barriers would have been a significant obstacle to entry into the craft market. The amount payable as membership fees in the different jurisdictions varied but was unlikely to have been insignificant compared with the incomes of the typical artisan in the seventeenth century. Moreover, the same was true of the penal sums for unlicensed dispensing; these were fixed across many localities at between five and ten florins, the latter being two to four weeks' average skilled artisan's earnings. In 1600 there were in excess of 100 guilds operating in major European cities and, by 1700, London's Society alone had 312 licensed practitioners while there were 278 in Paris (Wall, 1963; Brockliss and Jones, 1997).

Inspectorate powers strengthen a monopoly: the guild officials were empowered to inspect the stocks of traders who were suspected of dealing in worse materials; and, more deterrent, goods could be seized. These extensive powers, evident in the extensive records of London's municipal authorities, allowed the guilds to exercise regulatory control far beyond exclusion from the market (Cook, 1986).

Table 1. Guild regulatory structures across major European regions, c.1600–1700.

Region	Key Institution	Apprenticeship	Entry Fine	Members c.1680	Pricing Regime
England	Society of Apothecaries, London (charter 1617)	7 years	5–10 florins equiv.	312 (1650)	Municipal fixed tariff
France	Société des Apothicaires, Paris	5–6 years	Variable by guild	278 (1680)	Guild-set, flexible
Germany	Municipal guilds (fragmented)	5–7 years	5–8 florins	Variable	City-level ordinance
Italy	Trade-linked guilds, Florence/Venice	5–6 years	Local variation	High urban density	Market + tariff hybrid

Pharmaceutical Pricing Mechanisms

Pricing in the pre-industrial apothecary market was a function of input costs, taxing tariffs placed by the guild, import supply conditions and seasonal fluctuation of available botanicals.

The retail prices fixed by municipal ordinances for the fundamental herbal remedies hovered at a broad average of two or three shillings a piece in English markets. French livres-tournois equivalents yielded broadly comparable purchasing-power equivalents. Other compounded preparations, where a number of ingredients were mixed together, took longer to make and required more specialist knowledge also commanded prices of eight to twelve shillings, thus the charge for labour was occluded by the informational rents of guild membership. Relative to the raw material costs, the retail prices yielded margins of between 300–400 percent. Such accounts could make pharmaceuticals retailers pre-industrial craft activity with the highest profit margins.

Import dependency was the most volatile element in the cost structure. Exotic botanicals, including cinnamon sourced via Levantine trade networks, nutmeg from the Moluccas (increasingly under Dutch monopoly control after 1600), and cinchona bark from Andean sources (introduced to European markets in the 1630s), were priced five to tenfold above local herbs. Seasonal supply shocks documented in Florentine trade records as causing price increases of 20–30 per cent in poor harvest years transmitted directly to retail prices in markets with limited inventory buffering. The effect was to make compounded remedies incorporating imported ingredients luxury goods in all but the wealthiest urban markets.

Table 2. Pharmaceutical pricing structure in pre-industrial European apothecary markets.

Price Component	Category	Price Range	Profit Margin	Access Implication
Basic herbal decoction	Common remedy	2–3 shillings	Moderate	Accessible to urban middle classes
Compound medicine (local ingredients)	Intermediate	5–8 shillings	200–300%	Affordable to merchant households
Compound medicine (imported ingredients)	Premium	8–12 shillings	300–400%	Restricted to urban elites
Exotic botanical (e.g. cinchona bark)	Luxury/specialist	5–10× local herb cost	>400%	Elite-only; limited availability
Raw material (local herbs)	Input cost	Baseline		Widely available

Consumer Access and Social Stratification

Consumer access to guild-certified pharmaceutical products was shaped by three intersecting variables: geographic location relative to urban centres where practitioners were concentrated, socio-economic position determining affordability of different remedy categories, and literacy, which determined the capacity to navigate written prescriptions and guild-certified pharmacopoeia[44,45].

In urban locations, the extent to which access was available was evident among the commercial classes. Statutory survey data from seventeenth-century London and Paris

revealed a regular buying habit in 80 85% of merchant households for apothecary goods, while items of domestic employment and a written record of the household expenditure (a signifier of literacy and social learning) reached a heady 90 94% (Wallis, 2002; Pelling, 2003). For artisan households in these two towns, the frequency of regular use was smaller though still substantive and ranged from 40 60% (ibid.)[46,47].

In every one of the four regions, the rural populations were seriously underserved. Survey evidence from German areas suggests that less than 30 percent of rural households paid guild-certified apothecaries for prescriptions other rural residents used itinerant healers, wise women, monastic medicine, or just misapplied traditional knowledge handed down orally by ancestors (Rankin, 2013). The economic reasons are simple: not enough people in the rural areas could sustain the economics of a licensed apothecary practice that is to say, one that involves capital outlay for stock, equipment, and premises, plus guild dues[48,49].

Economic stratification was also entirely separate to geographical difference. In the urban market, the pice gradient between low-grade herbal preparations (two or three shilling) and imported compound medicines (eight to twelve shilling) essentially divided the market into two tiers; luxurious middle-class households drew on both, the upper income and the middle income households bought mainly from the lower tier, and the lower income/poor laboring class could only afford to access the service when absolutely necessary or by a charitable hand[50,51].

Table 3. Consumer access to pharmaceutical goods by social group and geographic location, c.1600–1700[52].

Consumer Group	Location	Estimated Access Rate	Remedy Category Accessed	Primary Constraint
Merchant/elite households	Urban	80–85%	Full range including imports	None (price-insensitive)
Artisan/middling households	Urban	40–60%	Basic to intermediate	Price sensitivity
Labouring poor	Urban	15–25%	Basic herbal only	Affordability; low literacy
Rural households (Germany)	Rural	<30%	Mostly basic/folk	Geographic distance; no guild presence
Rural households (N. Italy)	Rural	40–50%	Basic; trade access	Distance; partial coverage
Rural households (England/France)	Rural	25–40%	Basic herbal	Distance; limited guild supply

Economic Impact: Pharmaceuticals as Commodities

In addition to their role as inputs for medicine production, pharmaceuticals in pre-industrial Europe represented a unique category of commodity with quantifiable fiscal, commercial and distributional implications.

Fiscality appeared to matter. State licensing fees, tax levies on imported botanical goods, excise duties on apothecary sales these urban revenues (from London’s guild, from tolls on Florentine

spice and botanical imports, as explicit excise from the Florence customs records to finance the purchase of pharmaceuticals) were dispersed across the four regions as elsewhere in European commercial cities[53].

Trade also linked apothecaries to the earliest stages of European global trade. The demand for botanical supplies from Asia and the Americas provided a powerful commercial incentive for longdistance trade that predated and in some respects drove the development of the formal colonial trade infrastructure[54]. Monopoly control over the trade in nutmeg and clove by the Dutch East India Company after 1600, and later monopoly control of cinchona bark exports to Europe from the Spanish and Portuguese colonies, meant that European apothecaries supplies were in effect priced according to decisions taken thousands of miles from the point of sale, an early example of the supply-chain dependencies that characterize our modern pharmaceutical markets (Nightingale, 1995; Porter, 1997)[55,56].

Systemic Dimension: The systemic dimension has already been identified above in relation to consumer access, but is worth highlighting as a systemic feature. The high profit margins of 300–400% observed in trade books were not figures that would have been considered uniquely disreputable in a pre-industrial economy, but they were high nonetheless, and protected from competition by institutional mechanisms guild monopolies that kept the relatively modest costs from being competed away[57,58]. The result of the system was that drug industry profits were largely available only to the practitioners with existing guild privileges who kept costs low for themselves, and consumers with the fewest alternatives[59,60].

Table 4. Economic dimensions of pre-industrial pharmaceutical trade in European markets[61,62].

Dimension	Key Mechanism	Quantitative Evidence	Economic Significance
Fiscal contribution	Licensing fees, import levies, sales taxes	Significant share of municipal revenues	Embedded pharmacy in urban fiscal systems
Trade integration	Import of exotic botanicals	Exotic materials 5–10× local herb prices	Linked European healthcare to global commerce
Monopoly rents	Guild exclusion and tariff-fixing	Margins of 300–400% over raw costs	Sustained practitioner incomes above competitive levels
Distributional effects	Price stratification by class/geography	80–85% urban elite vs <30% rural access	Reinforced socio-economic health inequalities
Supply chain volatility	Harvest failures, trade disruptions	20–30% price spikes in poor harvest years	Consumer prices unstable; rural exposure highest




Figure 3. Pharmaceutical trade network model: European apothecary supply chains, c.1600–1700.

Discussion

Monopoly, Regulation, and Market Efficiency

The evidence assembled above supports a reading of apothecary guilds as monopolistic institutions whose regulatory functions were inseparable from their rent-generating purposes. This is not to argue that guilds were simply predatory the standardisation of training, the enforcement of quality controls, and the reduction of consumer uncertainty about practitioner competence were genuine social benefits that a deregulated market would not automatically have provided. Yet these benefits were bundled with market exclusion, price-fixing, and the suppression of potentially welfare-improving competition in ways that served incumbent practitioners at least as much as consumers[63,64].

The parallel with modern pharmaceutical regulation is instructive. Contemporary patent systems, regulatory approval requirements, and professional licensing arrangements similarly combine genuine quality-assurance functions with barriers to competition that sustain above-competitive pricing. The historical analysis suggests that this bundling of regulation and rent-seeking is not an accidental feature of pharmaceutical markets but a structural tendency arising from the combination of information asymmetry between practitioners and consumers, the public-good characteristics of pharmaceutical knowledge, and the political economy of professional associations (Fraser et al., 2025; Garattini et al., 2021)[65,66].

Pricing, Inequality, and the Limits of Tariff Regulation

The municipal tariff system was an early effort to address the problem of pricing medicines using government fiat. Fixed prices on standard remedies successfully prevented extreme gouging while permitting practitioners to cover costs and make acceptable profit margins. The

evidence suggests that the tariff system was a more successful approach to controlling prices of simple remedies than compounded or imported drugs, where manufacturers and buyers had much more scope for negotiation[67,68].

This also has contemporary relevance. Regulatory regimes now tend, on the whole, to be more effective for commoditised generic drugs than they are for specialist or patented pharmaceuticals, where information problems and monopolistically determined and limited substitutability confers market power on manufacturers. The historical evidence does not suggest that tariff regulation was a dead loss; it only implies that the benefits of redistribution were shouldered by urban middle-class consumers rather than the destitute for whom, in any case, markets in pharmaceuticals were never closed by tariffs[69,70].

Geographic Inequality and the Structural Logic of Underservice

The brutal rural–urban gradient in access to pharmaceuticals noted in all four regions exemplifies an underlying, structural logic, rather than a policy failure in any literal sense. Guildlicensed apothecaries established themselves in urban towns and cities because that is where the economics of licit practice made sense. No regulatory intervention short of public subsidy could ever have changed this basic equation, and the evidence does not show that pre-industrial states were willing to subsidize rural pharmaceuticals on any large scale[71,72].

What does this mean for the course of economic history? It means that early modern pharmaceutical markets were systematically skewed against the rural populations of Europe, and that this distortion could not be offset by the available regulatory mechanisms. This is eerily similar to the situation of modern healthcare distribution in low- and middle-income countries; the privatized provision of pharmaceuticals is confined to city markets, leaving the rural population to obtain medicines from unofficial sources[73,74].




Figure 4. Guild regulation and pharmaceutical pricing framework in pre-industrial European markets.



Comparative Regional Analysis

Sampled regional variation for England, France, Germany and Italy show that the guild, price, consumer link was not predetermined and fixed but was contingent on polity governance, trade geography and urban hierarchy[75].

England

The apothecary system in England was fairly early to develop centralisation consolidation under the Society of Apothecaries, which was granted its charter in 1617. The society had considerable control of practice in London, imposing seven year terms of apprenticeship and tariffs which in effect provided a level of market stability that was at least unusual for Europe. The Rose Case of 1703 proved apothecaries able to prescribe as well as dispense thus extending the range of their economic power though this is after the period that is central to this paper. Centralisation in the English system was at once a blessing and a curse. While formidable metropolitan regulation generated a comparatively orderly urban market, it failed to reach provincial towns or country villages where apothecaries were chronically few in number during the long seventeenth century. Lacking infrastructure for apothecaries in much of the country, rural England continued to rely to a large degree on the same type of unlicensed practitioners and folk-medical practices found elsewhere in Europe where regulation was less comprehensive[76,77].

France

All three countries displayed an ongoing tension in their relations between the guild authority of Paris with the diversity of provincial practices. The Societe des Apothicaires was an exclusively Parisian organization with a strong influence in the capital (where 278 members represents a significant part of the urban pharmaceutical manpower) but was finally hampered in its any assertion of regional reach by the patchy provision of French provincial government prior to the eighteenth century administrative reforms. Brockliss and Jones (1997) illustrate how provincial apothecaries often functioned within a less restrictive regime than the Paris one both in terms of differing cost considerations and administrative enforcement capabilities. The premium of 12-15 livres that medicines on the Parisian market could command against the more modest prices in the provincial towns was due to both the higher concentration of high-income consumers and the higher overhead costs of doing business in a congested urban environment. This gradient in prices demonstrated a more general industry maxim: even within a single nation regulated markets segmented on local demographic market[78,79].

Germany

In the German case the degree of fragmentation of political authority in the Holy Roman Empire (with its fragmented commercial regulation) was therefore translated into a similarly fragmented regulation of medicine. The guilds controlling pharmaceutical manufacture and sale in major imperial cities like Augsburg, Nuremberg and Frankfurt were quite independent from each other, and from any single imperial authority[80,81]. This fragmentation could have a mixed effect: it opened up political space for experiments in neighboring territories, but in turn created significantly uneven political space: small towns in (German) states had no access to licensed apothecaries in their midst; and rural territories, numerous and insufficient to support a licensed apothecary per town, would have had no licensed apothecary at all. The fact that in the German territories, less than 40 percent of towns between 5000 and 15000 inhabitants had access to licensed apothecaries, is an illustration of this inequality[82,83].

Italy

Italian apothecary economics was shaped decisively by trade geography. Cities with direct access to Mediterranean commerce Venice, Florence, Genoa benefited from lower import costs for botanical materials than any other European region, enabling apothecaries to compound exotic remedies at prices somewhat below those prevailing in northern markets. The downside of this trade integration was a sharper luxury gradient: the availability of exotic imported materials made it economically rational for Italian apothecaries to orient their higher-margin business toward elite consumers, whilst basic provision for the poor was correspondingly de-emphasized[84,85].

The figure of 92 per cent of Italian towns above 5,000 inhabitants hosting apothecaries the highest regional rate documented in this study reflects the urbanisation of Northern Italy rather than equitable distribution: it captures access for urban populations whilst saying nothing about the smaller towns and rural communities where the majority of the Italian population lived[86].

Table 5. Comparative regional analysis of apothecary economics.

Dimension	England	France	Germany	Italy
Regulatory model	Centralised (London charter)	Capital-dominated, fragmented provinces	Municipal fragmentation	Trade-linked guild network
Apprenticeship	7 years	5–6 years	5–7 years	5–6 years
Basic remedy price	2–3 shillings	~2–3 livres-tournois	Variable (city)	Variable + trade premium
Compound medicine price	8–12 shillings	12–15 livres	Variable	Elevated by imports
Urban access rate	~80% merchant HH	~80% Parisian elites	High in large cities	92% towns >5,000 pop.
Rural access rate	~25–35%	~30–40%	<40% towns <5,000 pop.	Below 50% rural areas
Import dependency	High (Levant, Americas)	Moderate–High	Moderate	High (Mediterranean)




Figure 5. Urban versus rural consumer access to pharmaceutical goods across European regions, c.1650.

Economic Implications

The economic implications of the apothecary system extend beyond the pharmaceutical sector to broader questions about the political economy of regulated markets in pre-industrial Europe.

First, the apothecary case provides unusually clear evidence of how professional associations succeeded in embedding regulatory authority within municipal governance structures a form of institutional capture that contemporary regulatory economics analyses under the heading of 'regulatory capture' (Garattini et al., 2021). The guild did not merely request that municipalities enforce its pricing rules; it negotiated the inclusion of those rules in municipal ordinances, creating a situation in which the regulatory apparatus of the state served the economic interests of the regulated profession[87,88].

Second, the integration of pharmaceutical markets into long-distance commodity trade during this period illustrates how apparently local regulatory structures were connected to global economic processes. The price of a compound remedy in London was determined not only by municipal tariff rules and guild membership structures but by harvest conditions in Ceylon, trade policy in the Dutch East Indies, and piracy rates in the Mediterranean. This global connectivity of local pharmaceutical prices has obvious contemporary resonances in debates about pharmaceutical supply chain security and import dependency[89,90].

Third, the evidence on consumer access raises questions about the distribution of the gains from pharmaceutical regulation. The quality-assurance functions of the guild system if taken at face value were real benefits, but they accrued disproportionately to consumers who were already well-placed: literate, urban, financially comfortable. Consumers who most needed quality assurance because they lacked the information to evaluate practitioners themselves the rural poor, the illiterate laboring classes were precisely those who were most systematically excluded from the regulated pharmaceutical market[91,92].



Modern Relevance and Legacy

The historical memory of pre-Industrial apothecary economics prompts direct comparison with current pharmaceutical governance in order that we may readily discern structures of differences and continuities.

The monopoly structure of guild regulation finds its modernized form in the patent system providing temporary market monopoly for new drugs in return for information about the formulations. Both systems sustain supra-competitive prices and are justified in the same way; as prices of quality assurance and incentive for investment; and both tend to restrict access to the better off over the poorer populations who are left with low quality and/or untaxed alternatives. Historical evidence indicates that this tradeoff is not an aberration but a permanent structural feature of the pharmaceutical markets where information asymmetries enable capture of regulation (Fraser et al., 2025)[93,94].

This pre-industrial municipal pricing system foreshadows the modern-day regime of regulation of drug prices, be it through reference pricing in European health systems, negotiated reimbursement prices in national health insurance schemes, or statutory price caps in low-income country markets. Past experience with tariff regulation highlights that price controls seem to work better for generic commodity-like drugs than for specialist or more complex preparations and has implications for the current discussions on differential pricing and value-based pricing (Garattini et al., 2021; International Pharmaceutical Federation, 2012) [95]. The import reliance revealed in pre-industrial trade records and the precariousness of supply which it enabled prefigures the modern debate on concentration in pharmaceutical supply chains, which finally emerged into policy visibility in the pandemic of COVID-19. The structural similarities are striking: in both seventeenth century and twenty-first, European markets for medicine were reliant on distant traders to supply essential active ingredients, and the disturbance of supply always led to the increase of prices and therefore inequality of access. Importantly, the urban-rural access gradient present in each of the four regions examined in this paper still characterizes the current global distribution of pharmaceutical access. While the mode of excess protective regulation, insurance gaps, and distribution flaws rather than guild monopolies is different, the structural result is still clearly in evidence: access to pharmaceuticals is heavily skewed towards high income urban areas (Jouss, 2024; Intuition Labs, 2026). Historical comparison does not alone point to policy options, but nonetheless shed light on the magnitude and durability of these structural forces[96].

Table 6. Historical apothecary economics and modern pharmaceutical parallels.

Historical Feature	Historical Evidence	Modern Parallel	Policy Relevance
Guild monopoly	Apprenticeship barriers; entry fines of 5–10 florins	Patent protection; regulatory approval barriers	Balancing innovation incentive with competitive access
Municipal tariff regulation	Fixed prices: 2–3 shillings basic, 8–12 shillings compound	Reference pricing; negotiated reimbursement	Price-control effectiveness varies by medicine type
Import	Exotic herbs 5–10×	API	Supply chain

dependency and volatility	local cost; 20–30% price spikes	concentration; pandemic supply disruption	security; stockpiling	strategic
Urban-rural access gradient	<30% rural vs 80–85% urban access	Healthcare desert; insurance coverage gaps	Universal policy; healthcare investment	access rural
Elite-commoner stratification	Complex compounds for elites; basic herbs for poor	Branded vs generic; high-cost specialist therapies	Affordability generic substitution	policy;

Limitations

Several limitations qualify the conclusions of this study. First, the archival sources on which the quantitative analysis rests are uneven in their geographic and chronological coverage. Guild records and municipal ordinances are substantially more complete for England and Northern Italy than for Germany and provincial France, creating a potential bias toward the regulatory systems of the better-documented regions.

Second, the consumer access statistics derived from municipal surveys and guild census records are estimates whose precision is difficult to verify against independent sources. The figures presented 80–85 per cent urban elite access, fewer than 30 per cent rural access in German territories reflect the best available evidence but should be treated as orders of magnitude rather than precise measurements[97].

Third, the study focuses on the four largest and best-documented European regions, excluding Iberia, the Low Countries, Scandinavia, and Eastern Europe, all of which had distinctive apothecary traditions that might qualify some of the generalisations offered here. Extending the comparative analysis to these regions would be a productive direction for future research.

Fourth, the historical-economic frameworks applied here monopoly theory, supply-and-demand analysis, consumer behaviour models are necessarily anachronistic in the sense that they impose conceptual categories developed in the modern period on earlier economic phenomena. This is a standard methodological challenge in economic history and does not invalidate the analysis, but it does require the reader to hold some analytical distance from the conclusions[7].

Conclusion

This study has examined the economics of pre-industrial European apothecaries across four analytical dimensions guild regulation, pharmaceutical pricing, consumer access, and economic impact drawing on guild charters, municipal records, and trade ledgers from England, France, Germany, and Italy between the fourteenth and eighteenth centuries.

The primary conclusions corroborate that apothecary guilds were formal monopolies, whose regulatory power was simultaneously quality-discipline-enforcing and rent-extracting. Entry to the market was effectively controlled by a five- to seven-year apprenticeship requirement and fines of five to ten florins on unlicensed practitioners, affording guild members a profit margin of 300–400 percent above the raw-material cost with abiding to municipal tariff ceilings on simple remedies. Heavy reliance on foreign off-island-botanicals gave rise to high volumetric-price volatility. Consumer access was highly unequal across both geographic and social axes: the 8085 per cent level for urban merchant households is sharply differentiated from that of

rural households in the German areas, where coverage was less than 30 per cent a difference reflecting the mismatch between the economics of licensed apothecary practice and the demand conditions of rural markets. Comparison across regions shows that centralised regulation (England) resulted in less spatial inequality within urban markets, but did not provide for dispersed rural markets; the capital-city-centric regulation (France) created a steep gradient in prices between the large, expensive capital and the more affordable provincial markets; institutional fragmentation (Germany) created the greatest spatial inequality; and trade-oriented provision (Italy) concentrated provision of exotic medicines among urban elites. The modern resonances of these findings are substantial. Patent protection, price-control regimes, supply-chain concentration, and urban-rural access gradients all have structural precedents in the pre-industrial pharmaceutical market. Historical analysis does not prescribe policy, but it illuminates the depth and persistence of the structural forces that shape pharmaceutical access forces that contemporary governance must engage with full awareness of their long-run institutional roots.

Future research might extend this comparative framework to Iberia, the Low Countries, and Scandinavia, and might examine in greater depth the mechanisms by which professional associations in other regulated sectors-maintained market monopolies over comparable historical periods.

Conflict of interest

The authors declare no conflicts of interest, financial or otherwise, relating to the research presented in this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors acknowledge institutional support from their respective affiliations.

Authers contribution

Anurag Verma: Conceptualization, formal analysis, writing (original draft), project administration.

Pragati Jain: Archival data collection, methodology, writing (review and editing).

Ashish Kumar Gupta: Literature review, comparative analysis, writing (review and editing).

Data availability statement

This study is based on historical archival sources. All primary sources cited are held in publicly accessible repositories or have been documented in the secondary literature referenced herein. No original datasets were generated.

Reference

1. Hope B. The Greatest Benefit to Mankind: A Medical History of Humanity From Antiquity to the Present. *BMJ: British Medical Journal* [Internet]. HarperCollins; 1998 [cited 2026 May 22];316:713. <https://pmc.ncbi.nlm.nih.gov/articles/PMC112708/>. Accessed 22 May 2026
2. Nikolić MM, Jovanović KK, Marković TL, Marković DL, Gligorijević NN, Radulović SS, et al. Antimicrobial synergism and cytotoxic properties of Citrus limon L., Piper nigrum L. and Melaleuca alternifolia (Maiden and Betche) Cheel essential oils. *Journal of Pharmacy and Pharmacology*. Blackwell Publishing Ltd; 2017;69:1606–14. <https://doi.org/10.1111/JPHP.12792>
3. Sherman PW, Billing J. Darwinian gastronomy: Why we use spices: Spices taste good because they are good for us. *Bioscience*. American Institute of Biological Sciences; 1999;49:453–63. <https://doi.org/10.2307/1313553>



4. 4. Lee EB, Shin KH, Woo WS. Pharmacological study on piperine. *Arch Pharm Res.* 1984;7:127–32. <https://doi.org/10.1007/BF02856625>
5. 5. Mamatha BS, Prakash M, Nagarajan S, Bhat KK. Evaluation of the flavor quality of pepper (*Piper nigrum* L.) cultivars by GC-MS, electronic nose and sensory analysis techniques. *J Sens Stud.* 2008;23:498–513. <https://doi.org/10.1111/J.1745-459X.2008.00168.X>
6. 6. Meghwal M. Nutritional Constituent of Black Pepper as Medicinal Molecules: A Review. *J Food Process Technol.* OMICS Publishing Group; 2012;01. <https://doi.org/10.4172/SCIENTIFICREPORTS.129>
7. 7. Spence EH. What Is Technology Good For? Stoic Philosophy and the Control Problem of AI Technology. *The Rowman & Littlefield Publishing Group;* 2025;11–26. <https://doi.org/10.5040/9798881810535.CH-2>
8. 8. Spence C. Behavioural Nudges, Physico-Chemical Solutions, and Sensory Strategies to Reduce People's Salt Consumption. *Foods.* MDPI; 2022;11. <https://doi.org/10.3390/FOODS11193092>
9. 9. Moss R, LeBlanc J, Ritchie C, Gorman M, Ettinger L, McSweeney MB. Effect of white pepper addition on the sensory perception of sodium-reduced soup with an emphasis on saltiness perception. *J Sens Stud.* John Wiley and Sons Inc; 2023;38. <https://doi.org/10.1111/JOSS.12874>
10. 10. Silver WL, Maruniak JA. Trigeminal chemoreception in the nasal and oral cavities. *Chem Senses.* 1981;6:295–305. <https://doi.org/10.1093/CHEMSE/6.4.295>
11. 11. Lai LH, Fu QH, Liu Y, Jiang K, Guo QM, Chen QY, et al. Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model. *Acta Pharmacol Sin.* 2012;33:523–30. <https://doi.org/10.1038/APS.2011.209>
12. 12. Liu L, Song G, Hu Y. GC-MS analysis of the essential oils of *Piper nigrum* L. and *Piper longum* L. *Chromatographia.* 2007;66:785–90. <https://doi.org/10.1365/S10337-007-0408-2>
13. 13. McNamara FN, Randall A, Gunthorpe MJ. Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1). *Br J Pharmacol.* 2005;144:781–90. <https://doi.org/10.1038/SJ.BJP.0706040>
14. 14. Lawless HT, Stevens DA. Responses by humans to oral chemical irritants as a function of locus of stimulation. *Percept Psychophys.* 1988;43:72–8. <https://doi.org/10.3758/BF03208975>
15. 15. Menon AN, Padmakumari KP. Studies on essential oil composition of cultivars of black pepper (*piper nigrum* L.)—V. *Journal of Essential Oil Research.* 2005;17:153–5. <https://doi.org/10.1080/10412905.2005.9698862>
16. 16. Smith SH. Demystifying a change in taste: Spices, space, and social hierarchy in Europe, 1380-1750. *International History Review.* Routledge; 2007;29:237–57. <https://doi.org/10.1080/07075332.2007.9641125>
17. 17. Rentmeister-Bryant H, Green BG. Perceived irritation during ingestion of capsaicin or piperine: Comparison of trigeminal and non-trigeminal areas. *Chem Senses.* 1997;22:257–66. <https://doi.org/10.1093/CHEMSE/22.3.257>
18. 18. Srinivasan K. Black pepper and its pungent principle-piperine: A review of diverse physiological effects. *Crit Rev Food Sci Nutr.* 2007;47:735–48. <https://doi.org/10.1080/10408390601062054>
19. 19. Liu H, Zeng FK, Wang QH, Wu HS, Tan LH. Studies on the chemical and flavor qualities of white pepper (*Piper nigrum* L.) derived from five new genotypes. *European Food Research and Technology.* Springer Verlag; 2013;237:245–51. <https://doi.org/10.1007/S00217-013-1986-X>
20. 20. Singh S, Kapoor IPS, Singh G, Schuff C, De Lampasona MP, Catalan CAN. Chemistry, antioxidant and antimicrobial potentials of white pepper (*Piper nigrum* L.) essential oil and



- oleoresins. Proceedings of the National Academy of Sciences India Section B - Biological Sciences. 2013;83:357–66. <https://doi.org/10.1007/S40011-012-0148-4>
21. 21. Rozin P. “Taste-smell confusions” and the duality of the olfactory sense. *Percept Psychophys.* 1982;31:397–401. <https://doi.org/10.3758/BF03202667>
22. 22. Khan M. Comparative physicochemical evaluation of fruits and antidepressant potential of volatile oils of fruits of local Piper species. *Oriental Journal of Chemistry.* Oriental Scientific Publishing Company; 2015;31:541–5. <https://doi.org/10.13005/OJC/310167>
23. 23. Mayer EE. Tanti non emo, sexte, piper: Pepper prices, Roman consumer culture, and the bulk of indo-roman trade. *Journal of the Economic and Social History of the Orient.* Brill Academic Publishers; 2018;61:560–89. <https://doi.org/10.1163/15685209-12341464>
24. 24. Liang J, Sun J, Chen P, Frazier J, Benefield V, Zhang M. Chemical analysis and classification of black pepper (*Piper nigrum* L.) based on their country of origin using mass spectrometric methods and chemometrics. *Food Research International.* Elsevier Ltd; 2021;140. <https://doi.org/10.1016/J.FOODRES.2020.109877>
25. 25. Joy N, Prasanth VP, Soniya E V. Microsatellite based analysis of genetic diversity of popular black pepper genotypes in South India. *Genetica.* 2011;139:1033–43. <https://doi.org/10.1007/S10709-011-9605-X>
26. 26. Liu DT, Besser G, Bayer K, Prem B, Mueller CA, Renner B. Bitter taste disrupts spatial discrimination of piperine-evoked burning sensations: A pilot study. *Biology (Basel).* MDPI; 2021;10. <https://doi.org/10.3390/BIOLOGY10090886>
27. 27. Spencer M, Dalton P. The third dimension of flavor: A chemesthetic approach to healthier eating (a review). *J Sens Stud.* Blackwell Publishing Ltd; 2020;35. <https://doi.org/10.1111/JOSS.12551>
28. 28. Rameshkumar KB, Aravind APA, Mathew PJ. Comparative phytochemical evaluation and antioxidant assay of piper longum L. and piper chaba hunter used in Indian traditional systems of medicine. *J Herbs Spices Med Plants.* Taylor & Francis Group LLC; 2011;17:351–60. <https://doi.org/10.1080/10496475.2011.632116>
29. 29. Milenković AN, Stanojević LP. BLACK PEPPER - CHEMICAL COMPOSITION AND BIOLOGICAL ACTIVITIES. *Advanced Technologies.* University of Nis; 2021;10:40–50. <https://doi.org/10.5937/SAVTEH2102040M>
30. 30. Spence C. The tongue map and the spatial modulation of taste perception. *Curr Res Food Sci* [Internet]. Elsevier B.V.; 2022 [cited 2026 May 22];5:598–610. <https://doi.org/10.1016/J.CRFS.2022.02.004>
31. 31. Haq IU, Imran M, Nadeem M, Tufail T, Gondal TA, Mubarak MS. Piperine: A review of its biological effects. *Phytotherapy Research* [Internet]. John Wiley and Sons Ltd; 2021 [cited 2026 May 22];35:680–700. <https://doi.org/10.1002/ptr.6855>
32. 32. Spence C. Garlic: Tracing its changing popularity in British cuisine. *Int J Gastron Food Sci* [Internet]. AZTI-Tecnalia; 2024 [cited 2026 May 22];35:324–40. <https://doi.org/10.1016/J.IJGFS.2023.100854>
33. 33. Rehman A, Mehmood MH, Haneef M, Gilani AH, Ilyas M, Siddiqui BS, et al. Potential of black pepper as a functional food for treatment of airways disorders. *J Funct Foods* [Internet]. Elsevier Ltd; 2015 [cited 2026 May 22];19:126–40. <https://doi.org/10.1016/J.JFF.2015.09.006>
34. 34. Spence C. The psychology of condiments: A review. *Int J Gastron Food Sci* [Internet]. AZTI-Tecnalia; 2018 [cited 2026 May 22];11:41–8. <https://doi.org/10.1016/J.IJGFS.2017.11.004>
35. 35. Aumpa P, Khawsud A, Jannu T, Renaldi G, Utama-Ang N, Bai-Ngew S, et al. Determination for a suitable ratio of dried black pepper and cinnamon powder in the

- development of mixed-spice ice cream. *Sci Rep* [Internet]. Nature Research; 2022 [cited 2026 May 22];12. <https://doi.org/10.1038/s41598-022-19451-7>
36. 36. Adefegha SA, Oboh G, Adefegha OM. Ashanti pepper (*Piper guineense* Schumacher et Thonn) attenuates carbohydrate hydrolyzing, blood pressure regulating and cholinergic enzymes in experimental type 2 diabetes rat model. *J Basic Clin Physiol Pharmacol*. Walter de Gruyter GmbH; 2017;28:19–30. <https://doi.org/10.1515/JBCPP-2016-0001>
37. 37. Freedman P. History of Spices. *Handbook of Eating and Drinking: Interdisciplinary Perspectives* [Internet]. Springer International Publishing; 2020 [cited 2026 May 22];77–91. https://doi.org/10.1007/978-3-030-14504-0_9/SAVE-RESEARCH
38. 38. Marselis D, Hordijk L. From blockbuster to “nichebuster”: How a flawed legislation helped create a new profit model for the drug industry. *The BMJ*. BMJ Publishing Group; 2020;370. <https://doi.org/10.1136/BMJ.M2983>
39. 39. Pröbster M, Rothe-Wulf A, Marsden N. Bias in AI Recommender Systems: Examining Gender Disparities in STEM and Non-STEM Career Recommendations for Professional Development. *Lecture Notes in Computer Science*. Springer Science and Business Media Deutschland GmbH; 2025;15820 LNAI:78–96. https://doi.org/10.1007/978-3-031-93415-5_5
40. 40. Marsden N. Prompting Fairness: How End Users Can Mitigate Bias in AI Systems. *Lecture Notes in Computer Science*. Springer Science and Business Media Deutschland GmbH; 2025;15820 LNAI:68–77. https://doi.org/10.1007/978-3-031-93415-5_4
41. 41. Johnson H, Beck R, Li W, Pateman A, Sediqi KM. A Synthesis of Reflections, Attitudes and Suggestions Towards Mindful Implementation of LLMs in Digital First Pathways. *Lecture Notes in Computer Science*. Springer Science and Business Media Deutschland GmbH; 2025;15820 LNAI:22–48. https://doi.org/10.1007/978-3-031-93415-5_2
42. 42. Drzyzga G. Incorporating Artificial Intelligence into Design Criteria Considerations. *Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)*. Springer Science and Business Media Deutschland GmbH; 2024;14735 LNAI:133–51. https://doi.org/10.1007/978-3-031-60611-3_10
43. 43. Umbrello S, Natale S. Reframing Deception for Human-Centered AI. *Int J Soc Robot*. Springer Science and Business Media B.V.; 2024;16:2223–41. <https://doi.org/10.1007/S12369-024-01184-4>
44. 44. Degen H, Ntoa S, editors. *Artificial Intelligence in HCI*. Cham: Springer Nature Switzerland; 2025 [cited 2026 May 17];15820. <https://doi.org/10.1007/978-3-031-93415-5>
45. 45. Ehsan U, Liao QV, Passi S, Riedl MO, Daumé HIII. Seamless XAI: Operationalizing Seamless Design in Explainable AI. *Proc ACM Hum Comput Interact*. Association for Computing Machinery; 2024;8. <https://doi.org/10.1145/3637396>
46. 46. Liao QV, Zhang Y, Luss R, Doshi-Velez F, Dhurandhar A. Connecting Algorithmic Research and Usage Contexts: A Perspective of Contextualized Evaluation for Explainable AI. *Proc AAAI Conf Hum Comput Crowdsourc*. Association for the Advancement of Artificial Intelligence; 2022;10:147–59. <https://doi.org/10.1609/hcomp.v10i1.21995>
47. 47. Mohamadi S, Mujtaba G, Le N, Doretto G, Adjeroh DA. ChatGPT in the Age of Generative AI and Large Language Models: A Concise Survey. 2023 [cited 2026 May 17]; <http://arxiv.org/abs/2307.04251>. Accessed 17 May 2026
48. 48. Dobbe RIJ. System safety and artificial intelligence. *The Oxford Handbook of AI Governance*. Oxford University Press; 2022;441–57. <https://doi.org/10.1093/oxfordhb/9780197579329.013.67>
49. 49. Chan CKY, Lee KKW. The AI generation gap: Are Gen Z students more interested in adopting generative AI such as ChatGPT in teaching and learning than their Gen X and



- millennial generation teachers? Smart Learning Environments. Springer; 2023;10. <https://doi.org/10.1186/s40561-023-00269-3>
50. 50. Liao QV, Xiao Z. Rethinking Model Evaluation as Narrowing the Socio-Technical Gap. 2025 [cited 2026 May 17]; <http://arxiv.org/abs/2306.03100>. Accessed 17 May 2026
51. 51. Stephanidis C, Salvendy G, Antona M, Duffy VG, Gao Q, Karwowski W, et al. Seven HCI Grand Challenges Revisited: Five-Year Progress. *Int J Hum Comput Interact* [Internet]. Taylor & Francis; 2025 [cited 2026 May 17];41:11947–95. <https://doi.org/10.1080/10447318.2025.2450411>
52. 52. Patterson D, Gonzalez J, Le Q, Liang C, Munguia L-M, Rothchild D, et al. Carbon Emissions and Large Neural Network Training. 2021 [cited 2026 May 17]; <http://arxiv.org/abs/2104.10350>. Accessed 17 May 2026
53. 53. Zang Y, Li W, Han J, Zhou K, Loy CC. Contextual Object Detection with Multimodal Large Language Models. *Int J Comput Vis.* Springer; 2025;133:825–43. <https://doi.org/10.1007/s11263-024-02214-4>
54. 54. Magrabi F, Ammenwerth E, McNair JB, De Keizer NF, Hyppönen H, Nykänen P, et al. Artificial Intelligence in Clinical Decision Support: Challenges for Evaluating AI and Practical Implications A Position Paper from the IMIA Technology Assessment & Quality Development in Health Informatics Working Group and the EFMI Working Group for As... *Yearb Med Inform.* Thieme Medical Publishers, Inc.; 2019;28:128–34. <https://doi.org/10.1055/S-0039-1677903>
55. 55. Srinivasu PN, Sivasai JG, Ijaz MF, Bhoi AK, Kim W, Kang JJ. Classification of skin disease using deep learning neural networks with mobilenet v2 and lstm. *Sensors.* MDPI AG; 2021;21. <https://doi.org/10.3390/S21082852>
56. 56. Praveen SP, Srinivasu PN, Shafi J, Wozniak M, Ijaz MF. ResNet-32 and FastAI for diagnoses of ductal carcinoma from 2D tissue slides. *Sci Rep. Nature Research;* 2022;12. <https://doi.org/10.1038/S41598-022-25089-2>
57. 57. Ahmad I, Merla A, Ali F, Shah B, AlZubi AA, AlZubi MA. A deep transfer learning approach for COVID-19 detection and exploring a sense of belonging with Diabetes. *Front Public Health.* Frontiers Media SA; 2023;11. <https://doi.org/10.3389/FPUBH.2023.1308404>
58. 58. Vulli A, Srinivasu PN, Sashank MSK, Shafi J, Choi J, Ijaz MF. Fine-Tuned DenseNet-169 for Breast Cancer Metastasis Prediction Using FastAI and 1-Cycle Policy. *Sensors.* MDPI; 2022;22. <https://doi.org/10.3390/S22082988>
59. 59. Kumar Y, Koul A, Singla R, Ijaz MF. Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. *J Ambient Intell Humaniz Comput.* Springer Science and Business Media Deutschland GmbH; 2023;14:8459–86. <https://doi.org/10.1007/S12652-021-03612-Z>
60. 60. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. *Heliyon* [Internet]. Elsevier Ltd; 2024 [cited 2026 May 17];10:e26297. <https://doi.org/10.1016/J.HELIYON.2024.E26297>
61. 61. Varkey B. Principles of Clinical Ethics and Their Application to Practice. *Medical Principles and Practice.* S. Karger AG; 2021;30:17–28. <https://doi.org/10.1159/000509119>
62. 62. Amisha, Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. *J Family Med Prim Care.* Ovid Technologies (Wolters Kluwer Health); 2019;8:2328–31. https://doi.org/10.4103/JFMPC.JFMPC_440_19
63. 63. Social Media Influencers in Healthcare and Pharma: What's Their Role? | by Cyn Meyer | Medium [Internet]. [cited 2026 May 17]. <https://medium.com/@cynmeyer/social-media-influencers-in-healthcare-and-pharma-whats-their-role-4484bb6b45d5>. Accessed 17 May 2026



64. 64. Byrne E, Kearney J, MacEvelly C. The Role of Influencer Marketing and Social Influencers in Public Health. Proceedings of the Nutrition Society [Internet]. Cambridge University Press (CUP); 2017 [cited 2026 May 17];76. <https://doi.org/10.1017/S0029665117001768>
65. 65. Wati DK, Sriatmi A, Arso SP. Role of Social Media and Digital Platforms in Healthcare Marketing: A Scoping Review. Journal of Public Health for Tropical and Coastal Region. Institute of Research and Community Services Diponegoro University (LPPM UNDIP); 2025;8:59–67. <https://doi.org/10.14710/JPHTCR.V8I1.24952>
66. 66. Jeyaraman M, Ramasubramanian S, Kumar S, Jeyaraman N, Selvaraj P, Nallakumarasamy A, et al. Multifaceted Role of Social Media in Healthcare: Opportunities, Challenges, and the Need for Quality Control. Cureus [Internet]. Springer Science and Business Media LLC; 2023 [cited 2026 May 17];15:e39111. <https://doi.org/10.7759/CUREUS.39111>
67. 67. Alves PG, Petersen I, Stevenson F. Searching for information on the risks of combined hormonal contraceptives on the internet: A qualitative study across six european countries. J Med Internet Res. JMIR Publications Inc.; 2019;21. <https://doi.org/10.2196/10810>
68. 68. Karim F, Oyewande A, Abdalla LF, Chaudhry Ehsanullah R, Khan S. Social Media Use and Its Connection to Mental Health: A Systematic Review. Cureus. Springer Science and Business Media LLC; 2020; <https://doi.org/10.7759/CUREUS.8627>
69. 69. Zotti F, Zotti R, Albanese M, Nocini PF, Paganelli C. Implementing post-orthodontic compliance among adolescents wearing removable retainers through whatsapp: A pilot study. Patient Prefer Adherence. Dove Medical Press Ltd.; 2019;13:609–15. <https://doi.org/10.2147/PPA.S200822>
70. 70. Latif MZ, Hussain I, Saeed R, Qureshi MA, Maqsood U. Use of smart phones and social media in medical education: Trends, advantages, challenges and barriers. Acta Informatica Medica. Avicena Publishing; 2019;27:133–8. <https://doi.org/10.5455/AIM.2019.27.133-138>
71. 71. Abroms LC. Public health in the Era of social media. Am J Public Health. American Public Health Association Inc.; 2019;109:S130–1. <https://doi.org/10.2105/AJPH.2018.304947>
72. 72. Naslund JA, Bondre A, Torous J, Aschbrenner KA. Social Media and Mental Health: Benefits, Risks, and Opportunities for Research and Practice. J Technol Behav Sci. Springer; 2020;5:245–57. <https://doi.org/10.1007/S41347-020-00134-X>
73. 73. Anagnostou A, Wang J, Chinthrajah S, Gupta R, Davis CM, Parrish C, et al. Addressing health disparities in food allergy: A Position Statement of the AAAAI Prior Authorization Task Force. Journal of Allergy and Clinical Immunology. Elsevier Inc.; 2025;155:53–61. <https://doi.org/10.1016/j.jaci.2024.10.008>
74. 74. Conway AE, Lieberman J, Codispoti CD, Mahdavinia M, Anagnostou A, Hsu Blatman KS, et al. Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone. Journal of Allergy and Clinical Immunology: In Practice. American Academy of Allergy, Asthma and Immunology; 2024;12:1170–80. <https://doi.org/10.1016/j.jaip.2024.02.039>
75. 75. Salgado TM, Patterson JA, Bajaj SK, Lajthia E, Zimmerman KM, Fernandez-Llimos F, et al. Characterization of pharmacy practice research centers across the United States. Research in Social and Administrative Pharmacy. Elsevier Inc.; 2020;16:230–7. <https://doi.org/10.1016/j.sapharm.2019.05.009>
76. 76. Hohmeier KC, Borja-Hart N, Cooper M, Kirby J, Fisher C. Training and retaining community pharmacy leaders: Career pathways after completing a PGY1 community pharmacy residency affiliated with a large supermarket chain. Journal of the American Pharmacists Association. Elsevier B.V.; 2017;57:82–5. <https://doi.org/10.1016/j.japh.2016.08.013>
77. 77. Pollini RA, Slocum S, Ozga JE, Joyce R, Xuan Z, Green TC, et al. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing



- order program. *Journal of the American Pharmacists Association*. Elsevier B.V.; 2022;62:1546–54. <https://doi.org/10.1016/j.japh.2022.03.015>
78. 78. Pednekar P, Peterson AM, Heller D. COMPARING MEDICATION ADHERENCE RATES BETWEEN PHARMACY DESERT AND NON-DESERT AREAS AMONG ELDERLY IN PENNSYLVANIA. *Value in Health*. Elsevier BV; 2016;19:A205–6. <https://doi.org/10.1016/j.jval.2016.03.1253>
79. 79. Widener MJ, Shannon J. When are food deserts? Integrating time into research on food accessibility. *Health Place*. Elsevier Ltd; 2014;30:1–3. <https://doi.org/10.1016/j.healthplace.2014.07.011>
80. 80. Sharareh N, Zheutlin AR, Qato DM, Guadamuz J, Bress A, Vos RO. Access to community pharmacies based on drive time and by rurality across the contiguous United States. *Journal of the American Pharmacists Association*. Elsevier B.V.; 2024;64:476–82. <https://doi.org/10.1016/j.japh.2024.01.004>
81. 81. Fisk-Hoffman RJ, Ranger SS, Gracy A, Gracy H, Manavalan P, Widmeyer M, et al. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida. *AIDS Patient Care STDS*. Mary Ann Liebert Inc.; 2024;38:275–85. <https://doi.org/10.1089/APC.2024.0067>
82. 82. Ying X, Kahn P, Mathis WS. Pharmacy deserts: More than where pharmacies are. *Journal of the American Pharmacists Association* [Internet]. Elsevier; 2022 [cited 2026 May 22];62:1875–9. <https://doi.org/10.1016/J.JAPH.2022.06.016>
83. 83. Pednekar P, Peterson A. Mapping pharmacy deserts and determining accessibility to community pharmacy services for elderly enrolled in a State Pharmaceutical Assistance Program. *PLoS One*. Public Library of Science; 2018;13. <https://doi.org/10.1371/JOURNAL.PONE.0198173>
84. 84. Lin SJ. Access to community pharmacies by the elderly in Illinois: A geographic information systems analysis. *J Med Syst*. 2004;28:301–9. <https://doi.org/10.1023/B:JOMS.0000032846.20676.94>
85. 85. Amstislavski P, Matthews A, Sheffield S, Maroko AR, Weedon J. Medication deserts: survey of neighborhood disparities in availability of prescription medications. *Int J Health Geogr*. 2012;11. <https://doi.org/10.1186/1476-072X-11-48>
86. 86. Geographical accessibility of medicines: a systematic literature review of pharmacy mapping - PMC [Internet]. [cited 2026 May 22]. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7931596/>. Accessed 22 May 2026
87. 87. Qato DM, Wilder J, Zenk S, Davis A, Makelarski J, Lindau ST. Pharmacy accessibility and cost-related underuse of prescription medications in low-income Black and Hispanic urban communities. *Journal of the American Pharmacists Association*. Elsevier B.V.; 2017;57:162–169.e1. <https://doi.org/10.1016/J.JAPH.2016.12.065>
88. 88. Casey MM, Klingner J, Moscovice I. Pharmacy services in rural areas: Is the problem geographic access or financial access? *Journal of Rural Health*. National Rural Health Association; 2002;18:467–77. <https://doi.org/10.1111/J.1748-0361.2002.TB00911.X>
89. 89. Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. *PLoS One*. Public Library of Science; 2017;12. <https://doi.org/10.1371/JOURNAL.PONE.0183172>
90. 90. Ikram SZ, Hu Y, Wang F. Disparities in Spatial Accessibility of Pharmacies in Baton Rouge, Louisiana. *Geogr Rev*. Wiley-Blackwell; 2015;105:492–510. <https://doi.org/10.1111/J.1931-0846.2015.12087.X>



91. 91. Chisholm-Burns MA, Spivey CA, Gatwood J, Wiss A, Hohmeier K, Erickson SR. Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services. *American Journal of Health-System Pharmacy*. American Society of Health-Systems Pharmacy; 2017;74:653–68. <https://doi.org/10.2146/AJHP150872>
92. 92. Padeiro M. Geographical accessibility to community pharmacies by the elderly in metropolitan Lisbon. *Research in Social and Administrative Pharmacy*. Elsevier Inc.; 2018;14:653–62. <https://doi.org/10.1016/J.SAPHARM.2017.07.014>
93. 93. Todd A, Copeland A, Husband A, Kasim A, Bambra C. Access all areas? An area-level analysis of accessibility to general practice and community pharmacy services in England by urbanity and social deprivation. *BMJ Open*. BMJ Publishing Group; 2015;5. <https://doi.org/10.1136/BMJOPEN-2014-007328>
94. 94. Rushworth GF, Cunningham S, Pflieger S, Hall J, Stewart D. A cross-sectional survey of the access of older people in the Scottish Highlands to general medical practices, community pharmacies and prescription medicines. *Research in Social and Administrative Pharmacy*. Elsevier Inc.; 2018;14:76–85. <https://doi.org/10.1016/J.SAPHARM.2017.01.002>
95. 95. Domnich A, Arata L, Amicizia D, Signori A, Gasparini R, Panatto D. Assessing spatial inequalities in accessing community pharmacies: A mixed geographically weighted approach. *Geospat Health*. Page Press Publications; 2016;11:240–50. <https://doi.org/10.4081/GH.2016.457>
96. 96. Todd A, Thomson K, Kasim A, Bambra C. Cutting care clusters: The creation of an inverse pharmacy care law? An area-level analysis exploring the clustering of community pharmacies in England. *BMJ Open*. BMJ Publishing Group; 2018;8. <https://doi.org/10.1136/BMJOPEN-2018-022109>
97. 97. Wirtz VJ, Hogerzeil H V., Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. *The Lancet*. Lancet Publishing Group; 2017;389:403–76. [https://doi.org/10.1016/S0140-6736\(16\)31599-9](https://doi.org/10.1016/S0140-6736(16)31599-9)